NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ
NovaBridge Biosciences (formerly I‑Mab, NASDAQ: IMAB) announced today that its corporate name change is now...
Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced today that its programmed death‑1...
InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC
China‑based InnoCare Pharma Limited (SHA: 688428, HKG: 9969) today disclosed that its self‑developed antibody‑drug conjugate...
National Health Commission Unveils Fourth Drug List for Generic Development
The National Health Commission (NHC) today released its fourth catalogue of medicines earmarked for generic...
BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third‑quarter earnings call that it no longer...
GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth
UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that...
Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment
Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG‑350A, a clinical‑stage oncolytic immunotherapy...
YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...
BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing
BioRay Pharmaceutical Co., Ltd. today announced the execution of a comprehensive license, supply, and commercialization...
IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea
IASO Biotherapeutics, a China‑based biotherapeutics developer, today announced a strategic collaboration agreement with GC Cell...
GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD
GlaxoSmithKline plc (GSK, NYSE: GSK) and Empirico Ltd. today announced a global exclusive licence agreement...
WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) today announced the signing of strategic Memoranda of...
Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N
Qyuns Therapeutics Co., Ltd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F. Hoffmann‑La...
Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced today that its self‑developed Class 1 anti‑HIV drug, ADC118...
Fosun Pharmaceutical Q3 2025 Revenue Slips 5.5% Amid VBP, Innovative Drugs Grow 18%
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today released its third‑quarter 2025 financial results....
Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its third‑quarter 2025 financial results....
Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today disclosed its intention to spin‑off...
Fosun Pharma Target Fund Launches with RMB 1 Billion Capital, Led by China Resources GP
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its controlled subsidiary,...
Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer
China‑based Alphamab Oncology (HKG: 9966) announced today that the U.S. Food and Drug Administration (FDA)...
SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round
China‑based SSY Group Limited (HKG: 2005) announced today that it has been pre‑selected as the...